Biological therapy for pustular psoriasis: a systematic review

Background The anecdotic evidence of the benefits from biologic agents for psoriasis is extensive. However, data on the efficacy of biologic agents for pustular psoriasis are limited. Methods To update the data on the efficacy and safety of biologic agents for the management of pustular psoriasis. A...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2020-03, Vol.59 (3), p.284-296
Main Authors: Falto‐Aizpurua, Leyre A., Martin‐Garcia, Rafael F., Carrasquillo, Osward Y., Nevares‐Pomales, Oscar W., Sánchez‐Flores, Xavier, Lorenzo‐Rios, Deyson
Format: Article
Language:English
Subjects:
Antagonists
Biological weapons
Clinical trials
Infliximab
Inhibitors
Management
Monoclonal antibodies
Psoriasis
Safety
Systematic review
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The anecdotic evidence of the benefits from biologic agents for psoriasis is extensive. However, data on the efficacy of biologic agents for pustular psoriasis are limited. Methods To update the data on the efficacy and safety of biologic agents for the management of pustular psoriasis. A systematic review of published data regarding biologic therapies on PubMED database, used in the management of pustular psoriasis from 2012 was undertaken. Results A total of 209 articles were identified, and 43 articles were selected for inclusion. TNF‐α inhibitors were used in 205 patients, and 86 patients received ustekinumab, secukinumab, brodalumab, ixekizumab and IL‐1 inhibitors. Overall response was favorable for most modalities. No serious adverse events were reported. Inconsistent measures of treatment response and study variability limited the overall evaluation of data. Conclusions Infliximab and ustekinumab have the most evidence of efficacy and safety for the treatment of pustular psoriasis. Recent evidence supports the use of IL‐17 antagonists. Prospective controlled and comparative trials are needed to further explore the efficacy and safety of biologic agents in order to establish objective recommendations for the management of this challenging condition.
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.14671